Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.36 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6890988 | 0.83 | ATM (0.42) | ATMPOLBOPRM1SMN1; SMN2OPRD1 | |
| SCHEMBL135585 | 0.82 | POLB (0.43) | ATMPOLBOPRM1SMN1; SMN2OPRD1 | |
| SCHEMBL15106045 | 0.81 | ATM (0.41) | ATMPOLBOPRM1SMN1; SMN2OPRD1 | |
| SCHEMBL69496 | 0.81 | ALDH1A1 (0.46) | ATMPOLBOPRM1SMN1; SMN2OPRD1 | |
| SCHEMBL18134201 | 0.81 | ALDH1A1 (0.46) | ATMPOLBOPRM1SMN1; SMN2OPRD1 | |
| SCHEMBL22280417 | 0.80 | ATM (0.41) | ATMPOLBOPRM1SMN1; SMN2OPRD1 | |
| SCHEMBL3133383 | 0.80 | ATM (0.46) | ATMPOLBOPRM1SMN1; SMN2OPRD1 | |
| SCHEMBL16639039 | 0.79 | ATM (0.40) | ATMPOLBMEN1KMT2AKDM4E | |
| SCHEMBL17048789 | 0.79 | ATM (0.40) | ATMPOLBOPRM1SMN1; SMN2OPRD1 | |
| SCHEMBL713102 | 0.77 | SMN1; SMN2 (0.46) | ATMPOLBOPRM1SMN1; SMN2OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580962-B2 | Spiroheterocyclic compounds as mGlu5 antagonists | RECORDATI IRELAND LTD. (IT) | 2013-11-12 | — | — | US | disclosed |
| US-20120059015-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LTD. (IT) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059015-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | GRM5, GPR65, GRIK5 | ATM 4299/4885POLB 4532/4885OPRM1 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.